Novo Nordisk A/S NVO
Set alert
At close · Nov 2
After hours · Nov 2, 5:05 PM ET
- YTD
- -20.50%
- 1 year
- -18.22%
- Open
- 40.10
- Prev close
- 40.00
- Mkt cap
- 178.41B
- Vol
- 10.88M
- Avg vol
- 12.69M
- EPS
- 4.09
- P/E
- 9.89
- Div yield
- 4.49%
More statistics
- Low
- 40.06
- High
- 40.78
- Forward P/E
- 11.76
- Beta
- 0.37
- Short ratio
- 2.52
- Inst. own
- 9.83%
- Dividend
- 1.80
- Ex-div date
- Aug 16, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 41.23
- 200-d avg
- 44.19
- 1y target
- 45.09
5D chart
Signals (94)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:45 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 3:40 PM | 1 hour ago |
| MACD: Buy Signal | Nov 2, 3:20 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 2:55 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 3 hours ago |
| SMA: Bullish | Nov 2, 12:50 PM | 4 hours ago |
| SMA: Bearish | Nov 2, 12:40 PM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 11:25 AM | 5 hours ago |
| RSI: Overbought | Nov 2, 11:05 AM | 6 hours ago |
| SMA: Bullish | Nov 2, 10:25 AM | 6 hours ago |
| SMA: Bearish | Nov 2, 10:10 AM | 7 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 7 hours ago |
| MACD: Buy Signal | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 30, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:40 AM | 4 days ago |
| RSI: Overbought | Oct 29, 11:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:25 PM | 5 days ago |
| RSI: Oversold | Oct 28, 11:55 AM | 5 days ago |
| RSI: Oversold | Oct 28, 11:25 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 6 days ago |
News
7 hours ago zacks.com
Novo Before Q3 Earnings: How Should Investors Play the Stock?
NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.
8 hours ago fool.com
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs
The market for GLP-1 drugs is forecast to explode. It may be understated still.
1 day ago fool.com
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Nordisk is one of two leading GLP-1 producers. The company is cutting prices on its GLP-1 drugs as it shifts toward a volume-driven model.
2 days ago benzinga.com
Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
3 days ago zacks.com
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 days ago fool.com
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.
4 days ago 247wallst.com
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the…
4 days ago benzinga.com
Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know
Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
5 days ago 247wallst.com
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.
5 days ago benzinga.com
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)
Novo Nordisk fails to block Eli Lilly’s weight-loss drug ads as a judge finds little evidence of market impact or lasting harm.
-
5 days ago benzinga.com
Novo Nordisk To Present 12 New Semaglutide And MASH Research Abstracts At AASLD’s The Liver Meeting 2026
The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASHNew post hoc data…
5 days ago zacks.com
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.
6 days ago seekingalpha.com
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick
Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth…
6 days ago fool.com
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net…
6 days ago defenseworld.net
Novo Nordisk A/S $NVO Stock Sold by Evergreen Capital Management LLC
Evergreen Capital Management LLC decreased its holdings in Novo Nordisk A/S (NYSE: NVO) by 15.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the…
1 week ago globenewswire.com
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies…
1 week ago marketbeat.com
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their…
1 week ago fool.com
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
1 week ago seekingalpha.com
Earn 12-15% Potential Income: Monthly Options Series (Nov. 2026)
Selling options can generate 12-15% annual income but requires discipline, risk management, and due diligence. We will discuss how to formulate a sustainable and repeatable income strategy for…
1 week ago seekingalpha.com
GreensKeeper Value Fund Q3 2026 Portfolio Activity
Our top performer in the third quarter was TVA Group, which gained 46.7%. TVA's first-half earnings reached levels not seen in over a decade. Intercontinental Exchange advanced 23.5% in Q3,…
1 week ago benzinga.com
More Americans Now Take GLP-1 Drugs for Weight Loss Than Diabetes as Food, Alcohol and Apparel Habits Shift, Survey Finds
GLP-1 users cut sweets and switch clothing sizes as weight management becomes top use.
1 week ago zacks.com
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
1 week ago fool.com
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
1 week ago defenseworld.net
48,696 Novo Nordisk A/S $NVO Shares Sold by Carnegie Investment Counsel
Carnegie Investment Counsel lowered its position in Novo Nordisk A/S (NYSE: NVO) by 28.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
1 week ago fool.com
Where Will Novo Stock Be in 10 Years?
Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.
1 week ago benzinga.com
Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
2 weeks ago benzinga.com
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
-
3 weeks ago benzinga.com
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.
3 weeks ago benzinga.com
Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’
PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.
4 weeks ago benzinga.com
FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug
FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outlook remains unchanged with 2027 launch goal.
1 month ago benzinga.com
Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms
Anthropic launches a $100 million academy to train 10,000 AI engineers by 2027 as demand for AI talent surges.
-
1 month ago benzinga.com
Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory Action On The BLA
https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html
1 month ago benzinga.com
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
1 month ago benzinga.com
Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports
Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.
-
1 month ago benzinga.com
Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat
Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooledsemaglutide 7.2 and 2.4 mg) reduced liver fat in adults…
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients switching to oral semaglutide also lost weight.
1 month ago benzinga.com
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
1 month ago benzinga.com
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data
Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo Nordisk's semaglutide treatments.
-
1 month ago benzinga.com
Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To Tirzepatide Up To 15 mg
Novo’s Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro®…
-
1 month ago benzinga.com
Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as…
1 month ago benzinga.com
Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question — Scientist Says He Had Already Studied the Enzymes for 4 Years
Anthropic’s Claude enzyme discovery claim faces scrutiny after a biologist questioned whether prior research influenced the AI’s findings.
-
1 month ago benzinga.com
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s…
1 month ago benzinga.com
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
1 month ago benzinga.com
What's Going on With Novo Nordisk Stock on Friday?
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting injectables.
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
1 month ago benzinga.com
Anthropic, OpenEvidence Expand Free AI Clinical Tool to 100 Countries: Report
Anthropic and OpenEvidence are giving doctors in nearly 100 poorer nations free access to medical guidance tools.
-
1 month ago benzinga.com
'Ozempic Maker Novo Open to Upgrading New York Listing' - FT
https://www.ft.com/content/00d53ca3-725f-4fa8-b452-cef562a13514?syn-25a6b1a6=1
-
1 month ago benzinga.com
3 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…